A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
HECHT, J. Randolph, MITCHELL, Edith, DEETER, Robert, SHAHIN, Seta, AMADO, Rafael G, CHIDIAC, Tarek, SCROGGIN, Carroll, HAGENSTAD, Christopher, SPIGEL, David, MARSHALL, John, COHN, Allen, MCCOLLUM, David, STELLA, Philip
Published in Journal of clinical oncology (10.02.2009)
Published in Journal of clinical oncology (10.02.2009)
Get full text
Journal Article
Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer
BENDELL, Johanna C, NEMUNAITIS, John, VUKELJA, Sasha J, HAGENSTAD, Christopher, CAMPOS, Luis T, HERMANN, Robert C, SPORTELLI, Peter, GARDNER, Lesa, RICHARDS, Donald A
Published in Journal of clinical oncology (20.11.2011)
Published in Journal of clinical oncology (20.11.2011)
Get full text
Journal Article
Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer
Hurvitz, Sara A, Bosserman, Linda D, Chan, David, Hagenstad, Christopher T, Kass, Frederick C, Smith, Frederick P, Rodriguez, Gladys I, Childs, Barrett H, Slamon, Dennis J
Published in SpringerPlus (12.05.2014)
Published in SpringerPlus (12.05.2014)
Get full text
Journal Article
Updated Results on the Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of the B-Cell Receptor Signaling Pathway
Sharman, Jeffrey P., Shustov, Andrei R., Smith, Mitchell R., Hagenstad, Christopher T., Kolibaba, Kathryn S., Abella-Dominicis, Esteban, Zhang, Danjie, Mitra, Siddhartha, Yasenchak, Christopher A., Awan, Farrukh T.
Published in Blood (02.12.2016)
Published in Blood (02.12.2016)
Get full text
Journal Article
Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of B-Cell Receptor Pathway Signaling
Sharman, Jeff P., Shustov, Andrei R., Smith, Mitchell R., Boyd, Thomas E., Hagenstad, Christopher, Kolibaba, Kathryn S., Abella, Steve, He, Jing, Eng, Clarence, Hu, Jing, Reddy, Anita, Mitra, Siddhartha, Yasenchak, Christopher A., Awan, Farrukh T.
Published in Blood (03.12.2015)
Published in Blood (03.12.2015)
Get full text
Journal Article
A Phase II Trial of Docetaxel With Bevacizumab as First-line Therapy for HER2-Negative Metastatic Breast Cancer (TORI B01)
Hurvitz, Sara A, Allen, Heather J, Moroose, Rebecca L, Chan, David, Hagenstad, Christopher, Applebaum, Steven H, Patel, Giribala, Hu, Eddie H, Ryba, Nancy, Lin, Lii-Shin, Wang, HeJing, Glaspy, John, Slamon, Dennis J, Kabbinavar, Fairooz
Published in Clinical breast cancer (01.08.2010)
Published in Clinical breast cancer (01.08.2010)
Get full text
Journal Article